AVALO THERAPEUTICS, INC. Accrued Liabilities and Other Liabilities
AVALO THERAPEUTICS, INC. (AVTX) had Accrued Liabilities and Other Liabilities of $17.78 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccruedLiabilitiesAndOtherLiabilities · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities and Other Liabilities $17.78M.
- 2026-03-31: Accrued Liabilities and Other Liabilities $11.24M.
- 2025-12-31: Accrued Liabilities and Other Liabilities $12.80M.
- 2025-09-30: Accrued Liabilities and Other Liabilities $7.50M.
| Period end | Accrued Liabilities and Other Liabilities | Accrued Liabilities and Other Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $17.78M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $11.24M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $12.80M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $7.50M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $6.52M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $4.57M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $6.32M 10-K · filed 2026-03-23 | |
| 2024-09-30 | $7.03M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $7.89M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $7.38M 10-Q/A · filed 2024-07-11 | |
| 2023-12-31 | $4.17M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $5.22M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $7.59M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $8.27M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $13.21M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $13.70M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $13.23M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $14.14M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $16.52M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $15.46M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $17.61M 10-Q · filed 2021-08-02 | |
| 2021-03-31 | $14.24M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $11.31M 10-K · filed 2022-03-02 | $11.31M 10-K · filed 2021-03-08 |
| 2020-09-30 | $8.81M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $6.49M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $6.19M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $5.64M 10-K · filed 2021-03-08 | |
| 2019-09-30 | $13.13M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $13.35M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $21.82M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $14.33M 10-K · filed 2020-03-11 | $19.73M 10-K · filed 2019-03-18 |
| 2018-09-30 | $18.17M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $10.33M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $7.74M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $7.53M 10-K · filed 2019-03-18 | $7.85M 10-K · filed 2018-04-02 |
| 2017-09-30 | $1.29M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $720.13K 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $638.98K 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $947.99K 10-K · filed 2018-04-02 | $942.43K 10-K · filed 2017-03-14 |
| 2016-09-30 | $3.36M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $2.40M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $2.15M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $1.89M 10-K · filed 2017-03-14 | |
| 2015-09-30 | $1.52M 10-Q · filed 2015-11-13 | |
| 2014-12-31 | $975.11K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |